Company Filing History:
Years Active: 2002-2004
Title: The Innovative Contributions of Osamu Johdo
Introduction
Osamu Johdo is a notable inventor based in Fujisawa, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of crystalline forms of anthracycline antibiotics. With a total of 3 patents to his name, Johdo's work has advanced the understanding and application of these important compounds.
Latest Patents
Johdo's latest patents include a crystalline anthracycline antibiotic and a process for producing the same. This patent discloses a crystalline form of anthracycline antibiotic characterized by specific 2θ values as measured by the X-ray diffraction method. The process involves crystallization using a specific poor solvent for the antibiotic combined with a good solvent, resulting in a crystalline form with excellent chemical and physical properties. Another significant patent is for the crystallization of doxorubicin hydrochloride. This patent outlines a method for crystallizing doxorubicin hydrochloride from a solution, particularly under conditions of 40°C or higher. The resulting crystalline aggregate exhibits excellent solubility in water, enhancing its potential for therapeutic applications.
Career Highlights
Osamu Johdo is currently associated with Mercian Corporation, where he continues to innovate in the pharmaceutical sector. His work has not only contributed to the scientific community but has also had practical implications in medicine, particularly in cancer treatment.
Collaborations
Johdo has collaborated with notable coworkers, including Takeo Yoshioka and Takuma Nakao. Their combined expertise has likely fostered a productive environment for research and development.
Conclusion
Osamu Johdo's contributions to the field of pharmaceuticals through his innovative patents demonstrate his commitment to advancing medical science. His work on crystalline forms of anthracycline antibiotics is particularly noteworthy, as it holds promise for improving drug efficacy and patient outcomes.